Use this A–Z evidence index to identify what a compound is, the mechanism researchers are examining, and how mature the evidence is. It completes the directory entries that do not yet have a dedicated long-form SRP guide.
Search all 59 research listings
Filter the live catalog, open a dedicated guide or evidence profile, and keep product information separate from educational research.
5-Amino-1MQ (20 mg Vial)
5-Amino-1MQ (50 mg Vial)
Adamax (10 mg Vial)
AOD-9604 (5 mg Vial)
ARA-290 (10 mg Vial)
BPC-157 (10 mg Vial)
BPC-157 (15 mg Vial)
BPC-157 (20 mg Vial)
BPC-157 + TB-500 (10/10 mg Vial) Wolverine Healing Stack
BPC-157 + TB-500 15/15 mg
Cagrilintide (10 mg Vial)
Cagrilintide (5 mg Vial)
Cerebrolysin (60 mg Vial)
Chonluten 20 mg
CJC-1295 DAC (5 mg Vial)
CJC-1295 No DAC (5 mg Vial)
Dihexa (5 mg Capsules, 30 Count)
DSIP (5 mg Vial)
Epitalon (10 mg Vial)
Epitalon (40 mg Vial)
Follistatin-344 (1 mg Vial)
FOXO4-DRI (10 mg Vial)
GHK-Cu (100 mg Vial)
GHK-Cu + KPV (50/10 mg Vial)
IGF-1 LR3 (1 mg Vial)
Ipamorelin (10 mg Vial)
Kisspeptin-10 (10 mg Vial)
KPV (10 mg Vial)
Livagen 20 mg
LL-37 (10 mg Vial)
Melanotan II (10 mg Vial)
MOTS-C (10 mg Vial)
MOTS-C (40 mg Vial)
NAD+ (1000 mg Vial)
NAD+ (500 mg Vial)
Ovagen 20 mg
Oxytocin (5 mg Vial)
Pancragen 20 mg
Pinealon (10 mg Vial)
Prostamax 20 mg
PT-141 (10 mg Vial)
Retatrutide (12 mg Vial)
Retatrutide (24 mg Vial)
Retatrutide (48 mg Vial)
Retatrutide (6 mg Vial)
Selank (10 mg Vial)
Semaglutide (10 mg Vial)
Semax (10 mg Vial)
Sermorelin (10 mg Vial)
SS-31 (10 mg Vial)
TB-500 (10 mg Vial)
Tesamorelin (10 mg Vial)
Thymosin Alpha-1 (10 mg Vial)
Tirzepatide (10 mg Vial)
Tirzepatide (100 mg Vial)
Tirzepatide (20 mg Vial)
Tirzepatide (30 mg Vial)
Tirzepatide (60 mg Vial)
Vesugen (20 mg Vial)
How we evaluate compounds
Evidence tiers reflect the strongest source type we located: established human biology, controlled clinical research, early human pharmacology, preclinical work, component-only evidence, or sparse evidence. We prioritize primary studies, trial records, regulatory documents, and PubMed-indexed literature. When a marketplace name is not chemically precise, we say so instead of guessing.
5-Amino-1MQ
Preclinical evidence
Metabolic research
Research overview
5-Amino-1MQ is a small-molecule inhibitor used to study nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide metabolism and cellular methyl-donor balance.
Mechanism under study
In experimental models, NNMT inhibition changes methylation-related metabolism and has been associated with altered adipose energy expenditure. This is a laboratory mechanism, not proof of a human weight-loss effect.
Evidence summary
Published evidence is primarily cell and animal research. A commonly cited mouse study reported improved metabolic measures after NNMT inhibition, but robust human efficacy and long-term safety data are not established.
Research-quality note
Confirm chemical identity and analytical purity. Do not treat data on NNMT biology as interchangeable with clinical evidence for this specific research compound.
Adamax
Identity/evidence uncertain
Neuroscience research
Research overview
Adamax is a trade-style name encountered in the research marketplace, but the exact sequence or formulation is not consistently defined in peer-reviewed literature.
Mechanism under study
A defensible mechanism cannot be assigned until the compound identity, sequence, and formulation are documented. Claims attached to a name alone should not be treated as pharmacology.
Evidence summary
We did not identify a stable, well-characterized body of indexed human evidence under this name. Research interpretation should begin with the supplier’s sequence disclosure, certificate of analysis, and independent identity testing.
Research-quality note
This is an evidence-gap entry. Verify identity before comparing it with Semax, ACTH fragments, or other neuroactive peptides.
AOD-9604
Preclinical; limited clinical evidence
Metabolic research
Research overview
AOD-9604 is a modified fragment derived from the C-terminal region of human growth hormone. It was developed to investigate whether selected metabolic actions could be separated from the full hormone’s growth-promoting activity.
Mechanism under study
Preclinical studies evaluated lipolysis and fat-oxidation pathways without the full receptor profile of intact growth hormone. Fragment biology should not be generalized to recombinant growth hormone.
Evidence summary
Animal and laboratory studies exist, while clinical development has not established a broadly accepted therapeutic role. Human efficacy, optimal exposure, and long-term safety remain uncertain.
Research-quality note
Require sequence confirmation and purity testing. Findings from animal obesity models are hypothesis-generating only.
ARA-290 (Cibinetide)
Early human evidence
Neuroimmune research
Research overview
ARA-290, also called cibinetide, is an erythropoietin-derived peptide designed to engage tissue-protective signaling without stimulating red-blood-cell production like full erythropoietin.
Mechanism under study
It is studied as an agonist of an innate repair receptor complex implicated in inflammation resolution, tissue protection, and small-fiber nerve biology.
Evidence summary
Small clinical studies have explored neuropathy and related inflammatory conditions. These trials are informative but not sufficient to establish broad clinical effectiveness or a standard research protocol.
Research-quality note
Distinguish cibinetide studies from studies of erythropoietin itself. Verify sequence and formulation when evaluating research materials.
Cagrilintide
Human clinical evidence; investigational
Metabolic research
Research overview
Cagrilintide is a long-acting amylin analogue investigated for appetite regulation and body-weight management, including in combination research with GLP-1–based agents.
Mechanism under study
Amylin-receptor signaling can influence satiation, gastric activity, and food intake. Combination effects must be evaluated from combination-specific trials rather than assumed from either component alone.
Evidence summary
Randomized clinical programs have reported weight-related outcomes, and later-stage trials are ongoing or recently reported. Regulatory status and approved indications can change, so current official records should be checked.
Research-quality note
Do not equate a research vial with a regulated clinical-trial or approved formulation. Confirm identity, potency, and current regulatory context.
Cerebrolysin
Human studies; heterogeneous evidence
Neuroscience research
Research overview
Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and amino acids rather than a single, precisely defined peptide.
Mechanism under study
Proposed neurotrophic and neuroprotective actions are based on mixture-level laboratory and clinical observations. Because it is a complex biological mixture, results cannot be assigned to one component.
Evidence summary
Clinical studies and systematic reviews span stroke, cognitive disorders, and brain injury, with variable designs and conclusions. Evidence is condition-specific and not uniformly accepted across guidelines or jurisdictions.
Research-quality note
Batch characterization and manufacturing controls are central. A single-compound certificate is not enough to characterize a complex peptide mixture.
Chonluten
Sparse/limited evidence
Peptide bioregulator research
Research overview
Chonluten is marketed as a short peptide bioregulator associated with respiratory-tissue research. The English-language, independently replicated evidence base is limited.
Mechanism under study
Proposed gene-regulatory and tissue-specific effects are largely derived from preclinical or regionally published bioregulator literature. The precise receptor-level mechanism is not well established.
Evidence summary
Available reports are not comparable in depth to large randomized drug-development programs. Independent replication, pharmacokinetics, and standardized human safety data remain important gaps.
Research-quality note
Verify the exact amino-acid sequence; trade names alone are insufficient for literature matching.
CJC-1295 with DAC
Early human pharmacology
Growth-hormone-axis research
Research overview
CJC-1295 is a growth-hormone-releasing-hormone analogue. The DAC version contains a drug-affinity complex designed for prolonged albumin binding and extended exposure.
Mechanism under study
It activates the GHRH receptor and can increase endogenous growth-hormone and IGF-1 signaling. DAC markedly changes pharmacokinetics, so DAC and non-DAC materials are not interchangeable.
Evidence summary
Early controlled human studies described sustained pharmacodynamic effects, but these do not establish broad therapeutic efficacy or long-term safety for research-market products.
Research-quality note
Require sequence and DAC-status confirmation. Mislabeling DAC versus non-DAC changes the scientific interpretation substantially.
CJC-1295 without DAC (Modified GRF 1-29)
Limited human pharmacology
Growth-hormone-axis research
Research overview
The label “CJC-1295 without DAC” is commonly used for a shorter-acting GHRH analogue, often described as modified GRF(1-29). Naming is inconsistent across suppliers.
Mechanism under study
Like other GHRH analogues, it stimulates pituitary GHRH receptors. Without an albumin-binding DAC, exposure is expected to be much shorter than true CJC-1295 DAC.
Evidence summary
Evidence is largely extrapolated from GHRH analogue pharmacology and small studies. Supplier terminology does not always correspond cleanly to compounds in the literature.
Research-quality note
Sequence confirmation is essential. Research reports should state the actual peptide sequence rather than relying only on “no DAC.”
Dihexa
Preclinical evidence
Neuroscience research
Research overview
Dihexa is an angiotensin IV–derived small molecule studied for effects on synaptic biology and cognition in experimental systems.
Mechanism under study
Preclinical work links Dihexa to hepatocyte growth factor/c-Met signaling and synaptogenesis. This pathway also has roles in cell growth, making mechanism-based safety questions important.
Evidence summary
Published work is dominated by cell and animal models. Controlled human efficacy, pharmacokinetics, and long-term safety have not been established.
Research-quality note
Do not translate rodent cognitive findings directly to people. Confirm chemical identity because Dihexa is not a conventional peptide despite its derivation.
DSIP
Older, inconsistent evidence
Sleep and neuroendocrine research
Research overview
Delta sleep-inducing peptide (DSIP) is a small peptide first described in sleep-related experiments. Its biological identity, endogenous role, and reproducibility have been debated.
Mechanism under study
Reported effects span sleep architecture, stress signaling, and neuroendocrine regulation, but no single well-validated receptor mechanism explains the historical literature.
Evidence summary
Much of the literature is older, small, or methodologically heterogeneous. Modern replication and well-controlled human pharmacology are limited.
Research-quality note
Treat broad sleep or recovery claims cautiously and document analytical identity in any laboratory work.
Epitalon
Preclinical/small human literature
Aging-biology research
Research overview
Epitalon (also spelled Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly, studied mainly in aging, pineal, and telomere-related research.
Mechanism under study
Reported laboratory effects include changes in gene expression, oxidative processes, and telomerase activity. These proposed mechanisms remain context-dependent and do not demonstrate lifespan extension in humans.
Evidence summary
The evidence base consists largely of preclinical work and small or regionally published human studies. Large independent randomized trials are lacking.
Research-quality note
Search both spellings and verify the four-amino-acid sequence when matching a material to the literature.
Follistatin-344
Preclinical/biologic research
Muscle-signaling research
Research overview
Follistatin-344 is a precursor isoform of follistatin, a binding protein that regulates activins and related TGF-beta-family ligands, including pathways connected to myostatin.
Mechanism under study
By binding activins and myostatin-related ligands, follistatin can alter muscle, reproductive, and metabolic signaling. Effects are broad and not limited to muscle tissue.
Evidence summary
Strong pathway biology and animal research exist, along with experimental gene-therapy work. Evidence for unregulated recombinant research products is not equivalent to those controlled platforms.
Research-quality note
Isoform, folding, glycosylation, bioactivity, and endotoxin testing matter; mass alone does not establish a functional protein product.
FOXO4-DRI
Preclinical evidence
Cellular-senescence research
Research overview
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt interaction between FOXO4 and p53 in senescent cells.
Mechanism under study
In experimental models, disrupting FOXO4-p53 signaling promoted apoptosis in selected senescent cells and improved some tissue-function measures in aged mice.
Evidence summary
The influential evidence is preclinical. Human pharmacokinetics, selectivity, efficacy, and long-term safety are not established, and senolytic effects may vary by cell type.
Research-quality note
Sequence stereochemistry is critical: D-retro-inverso design cannot be inferred from molecular weight alone.
GHK-Cu + KPV Blend
Component-level evidence only
Tissue and inflammation research
Research overview
This blend combines copper-binding GHK-Cu with KPV, an alpha-MSH-derived tripeptide. Each component has a distinct literature base.
Mechanism under study
GHK-Cu is studied in extracellular-matrix, wound, and skin biology; KPV is studied in preclinical inflammatory signaling. A mixture may not reproduce either component’s isolated behavior.
Evidence summary
We found component-level research but no robust body of peer-reviewed, blend-specific clinical evidence. Claims should be attributed to the individual components unless a study tests the exact formulation.
Research-quality note
Confirm both peptide identities, copper complexation, ratio, purity, and compatibility. Do not merge separate evidence streams into a combination claim.
IGF-1 LR3
Laboratory reagent evidence
Growth-factor research
Research overview
Long R3 IGF-1 is a modified insulin-like growth factor analogue engineered for reduced binding to IGF-binding proteins and prolonged activity in laboratory systems.
Mechanism under study
It activates IGF-1 receptor signaling and downstream growth, survival, and metabolic pathways. These pathways are pleiotropic and can affect many tissues.
Evidence summary
IGF-1 LR3 is widely used as a cell-culture and animal-research reagent, but there is no established general clinical role for research-market LR3 products.
Research-quality note
Bioactivity, correct folding, aggregation, sterility, and endotoxin are crucial for interpreting protein-reagent results.
Ipamorelin
Early human pharmacology
Growth-hormone-axis research
Research overview
Ipamorelin is a selective growth-hormone secretagogue and ghrelin-receptor agonist studied for its ability to stimulate pulsatile growth-hormone release.
Mechanism under study
It activates GHSR1a signaling at the pituitary and hypothalamic axis. Its selectivity profile differs from older secretagogues, but endocrine effects remain system-wide.
Evidence summary
Early human pharmacokinetic and pharmacodynamic studies exist. They characterize hormone release more clearly than they establish long-term clinical outcomes.
Research-quality note
Do not treat biomarker changes as demonstrated functional benefit. Combination studies require evidence for the exact combination.
Kisspeptin-10
Human mechanistic evidence
Reproductive-axis research
Research overview
Kisspeptin-10 is the active C-terminal decapeptide of kisspeptin and a potent agonist of the KISS1 receptor, a central regulator of reproductive hormone signaling.
Mechanism under study
KISS1R activation stimulates hypothalamic GnRH release, which can alter luteinizing hormone and follicle-stimulating hormone secretion.
Evidence summary
Controlled human mechanistic studies have examined reproductive endocrinology and assisted-reproduction contexts. Outcomes depend on sex, hormonal state, and study design.
Research-quality note
Kisspeptin-10 and longer kisspeptin forms have different pharmacokinetics; record the exact molecular form.
KPV
Preclinical evidence
Inflammation research
Research overview
KPV is the C-terminal tripeptide Lys-Pro-Val derived from alpha-melanocyte-stimulating hormone and studied for anti-inflammatory activity.
Mechanism under study
Laboratory studies report effects on inflammatory transcription and epithelial immune responses, including pathways involving NF-kappaB. A definitive standalone receptor mechanism remains under study.
Evidence summary
Most evidence is from cell and animal models, including intestinal and skin-related research. Controlled human efficacy and safety evidence are limited.
Research-quality note
Distinguish KPV-specific data from data on full-length alpha-MSH or other melanocortin agonists.
Livagen
Sparse/limited evidence
Peptide bioregulator research
Research overview
Livagen is marketed as a short peptide bioregulator associated with liver-related research. Publicly indexed, independently replicated evidence is limited.
Mechanism under study
Proposed gene-expression and tissue-regulatory effects are largely described in preclinical or regional bioregulator literature rather than a widely validated receptor model.
Evidence summary
Large randomized human trials, standardized pharmacokinetics, and broad independent replication are lacking.
Research-quality note
Verify the disclosed sequence and do not use a trade name as a substitute for molecular identification.
LL-37
Strong mechanistic; limited therapeutic evidence
Innate-immunity research
Research overview
LL-37 is the only human cathelicidin antimicrobial peptide and is produced from the precursor hCAP18.
Mechanism under study
It can disrupt microbial membranes and also modulate chemotaxis, inflammation, wound responses, and nucleic-acid sensing. Activity is highly dependent on concentration and biological environment.
Evidence summary
There is extensive laboratory and disease-association literature, but therapeutic delivery, selectivity, toxicity, and clinical efficacy remain challenging.
Research-quality note
Results depend on salt conditions, aggregation, oxidation, and endotoxin control. Endogenous biology does not establish safety of exogenous research material.
Melanotan II
Limited human evidence; safety concerns
Melanocortin research
Research overview
Melanotan II is a synthetic cyclic analogue of alpha-MSH that activates multiple melanocortin receptors.
Mechanism under study
Melanocortin receptor activation can influence pigmentation, appetite, and sexual function. Its receptor profile is not highly selective.
Evidence summary
Small human studies and case reports exist, but it is not an approved tanning drug and uncontrolled products have been associated with adverse-event concerns.
Research-quality note
Do not confuse Melanotan II with afamelanotide, a regulated medicine with a different molecule and clinical context.
NAD+
Established biology; intervention-specific gaps
Cellular-metabolism research
Research overview
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme in redox metabolism and a substrate for enzymes such as sirtuins and PARPs. It is not a peptide.
Mechanism under study
NAD+/NADH couples support energy metabolism, while NAD+-consuming enzymes connect the molecule to DNA repair, stress responses, and signaling.
Evidence summary
The biology is extensive, but evidence for a particular exogenous NAD+ formulation, route, or claimed outcome must be evaluated separately. Precursor studies are not automatically evidence for NAD+ itself.
Research-quality note
State the exact molecular form, assay purity, and stability. Do not merge evidence for NR, NMN, niacin, and NAD+.
NAD+ biology review search · Human NAD+ intervention research
Ovagen
Sparse/limited evidence
Peptide bioregulator research
Research overview
Ovagen is marketed as a short peptide bioregulator associated with liver and gastrointestinal research in some catalogs. Definitions and naming may vary.
Mechanism under study
Claims generally refer to tissue-specific gene-regulatory effects, but a well-replicated receptor-level mechanism is not established.
Evidence summary
Independent, well-controlled human studies are sparse. Much of the available discussion is not equivalent to indexed clinical evidence.
Research-quality note
Verify sequence, nomenclature, and the intended tissue association before matching the product with publications.
Oxytocin
Extensive human biology and clinical use
Neuroendocrine research
Research overview
Oxytocin is a nine-amino-acid peptide hormone involved in uterine contraction, milk ejection, and central social and stress-related signaling.
Mechanism under study
It activates the oxytocin receptor, a G-protein-coupled receptor expressed in peripheral tissues and the nervous system. Context, route, and timing strongly affect results.
Evidence summary
Oxytocin has established prescription uses in regulated obstetric formulations and a large research literature. Findings in social-behavior studies are heterogeneous and should not be generalized.
Research-quality note
A research product is not equivalent to an approved medicine. Peptide stability, adsorption, and formulation can alter experimental exposure.
Pancragen
Sparse/limited evidence
Peptide bioregulator research
Research overview
Pancragen is a short peptide bioregulator associated with pancreatic-tissue research in regional literature.
Mechanism under study
Proposed actions involve gene-expression regulation and tissue homeostasis, but a broadly accepted molecular target has not been established.
Evidence summary
Evidence is primarily preclinical or from small, regionally published studies. Independent replication and standardized human safety data are limited.
Research-quality note
Confirm the exact peptide sequence and avoid extrapolating from general pancreatic peptides.
Pinealon
Preclinical/small human literature
Neuroscience bioregulator research
Research overview
Pinealon is a short peptide, commonly described as Glu-Asp-Arg, investigated in neuroprotective and aging-related bioregulator research.
Mechanism under study
Reported laboratory effects include changes in gene expression, oxidative stress, and neuronal survival. A definitive receptor and full pharmacology are not established.
Evidence summary
Most publications are preclinical or small and concentrated within a limited research network. Large independent randomized trials are lacking.
Research-quality note
Verify the three-amino-acid sequence and keep claims proportional to the limited evidence base.
Prostamax
Sparse/limited evidence
Peptide bioregulator research
Research overview
Prostamax is marketed as a short peptide bioregulator associated with prostate-tissue research.
Mechanism under study
Proposed tissue-regulatory effects come mainly from regional peptide-biogerontology literature; a validated receptor-level mechanism is not established.
Evidence summary
Independent replication, standardized pharmacokinetics, and large controlled human trials are sparse.
Research-quality note
Require exact sequence disclosure and do not infer equivalence to other prostate-derived peptide preparations.
PT-141 (Bremelanotide)
Human clinical evidence; regulated analogue context
Melanocortin research
Research overview
PT-141 is bremelanotide, a cyclic melanocortin-receptor agonist developed from melanocortin peptide research.
Mechanism under study
It acts centrally through melanocortin receptors involved in sexual response. Its mechanism differs from vasodilator drugs.
Evidence summary
A regulated prescription bremelanotide product has clinical-trial and labeling evidence for a specific indication. That evidence does not establish equivalence of an unapproved research vial.
Research-quality note
Check the current FDA label for the regulated product and distinguish it from research material in formulation, manufacturing, and oversight.
Selank
Limited human evidence
Neuroscience research
Research overview
Selank is a synthetic heptapeptide analogue related to the immunomodulatory peptide tuftsin and studied mainly in anxiety, cognition, and gene-expression research.
Mechanism under study
Proposed actions include modulation of neurotransmitter systems and immune-neural signaling, but no single mechanism fully explains the reported effects.
Evidence summary
Human reports exist, but the literature is geographically concentrated and often small. Large independent, internationally replicated trials are limited.
Research-quality note
Separate peer-reviewed findings from marketing claims and verify the full seven-amino-acid sequence.
Semax
Limited human evidence
Neuroscience research
Research overview
Semax is a synthetic ACTH(4-7)-derived heptapeptide studied in neuroprotection, cognition, and stress-related signaling.
Mechanism under study
Reported effects involve neurotrophic signaling, neurotransmitter systems, and gene expression without the classic adrenal steroidogenic activity of full ACTH.
Evidence summary
Clinical and preclinical publications exist, but much of the human evidence is regionally concentrated and not broadly replicated in large modern trials.
Research-quality note
Do not generalize from ACTH or other melanocortin fragments. Confirm the exact Semax sequence.
Sermorelin
Human pharmacology; historical clinical context
Growth-hormone-axis research
Research overview
Sermorelin is the 1-29 amino-acid fragment of human GHRH and retains the portion required to stimulate pituitary growth-hormone release.
Mechanism under study
It activates the GHRH receptor, relying on a functioning pituitary rather than directly supplying growth hormone.
Evidence summary
Human diagnostic and pediatric literature exists, including historical regulated-product use. This does not establish anti-aging or performance claims.
Research-quality note
Sermorelin, modified GRF(1-29), and CJC-1295 are related but chemically and pharmacokinetically distinct.
Thymosin Alpha-1
Human clinical evidence; context-specific
Immune research
Research overview
Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha and studied as an immune-modulating agent.
Mechanism under study
It influences innate and adaptive immune signaling, including dendritic-cell and T-cell responses. Effects vary with disease state and co-therapies.
Evidence summary
Clinical studies span infections, oncology adjunct research, and immune dysfunction. It is approved in some countries but not for all marketed claims or in every jurisdiction.
Research-quality note
Regulatory status, indication, and formulation must be checked by country. Research material is not equivalent to a regulated medicine.
Vesugen
Sparse/limited evidence
Peptide bioregulator research
Research overview
Vesugen is marketed as a short peptide bioregulator associated with vascular-tissue and endothelial research.
Mechanism under study
Proposed effects involve gene expression and vascular cell homeostasis, but a well-validated receptor-level mechanism is not established.
Evidence summary
Available evidence is mainly preclinical or from small regional studies. Independent replication and standardized human safety data are limited.
Research-quality note
Confirm the exact sequence and distinguish this material from other vascular peptide preparations.
Editorial standard: This index is a living evidence map, not a protocol library. Source coverage and regulatory status change. Entries should be reassessed when new trials, safety signals, or identity data become available. Last editorial review: August 2026.